These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15319800)

  • 1. Atomoxetine--treatment of attention deficit hyperactivity disorder: beyond stimulants.
    Thomason C; Michelson D
    Drugs Today (Barc); 2004 May; 40(5):465-73. PubMed ID: 15319800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
    Corman SL; Fedutes BA; Culley CM
    Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder.
    Vaughan B; Fegert J; Kratochvil CJ
    Expert Opin Pharmacother; 2009 Mar; 10(4):669-76. PubMed ID: 19239401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D; Plosker GL
    Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.
    Udvardi PT; Föhr KJ; Henes C; Liebau S; Dreyhaupt J; Boeckers TM; Ludolph AG
    Drug Des Devel Ther; 2013; 7():1433-46. PubMed ID: 24348020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.
    Caballero J; Nahata MC
    Clin Ther; 2003 Dec; 25(12):3065-83. PubMed ID: 14749146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.
    Bakken RJ; Paczkowski M; Kramer HP; Axelson AA; Williams DW; Malcolm SK; Sumner CR; Kelsey DK
    Curr Med Res Opin; 2008 Feb; 24(2):449-60. PubMed ID: 18179733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    CNS Drugs; 2010 Jan; 24(1):85-8. PubMed ID: 20030421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Close up on atomoxetine: a nonstimulant choice for treating ADHD.
    Allen C; Pitcock J
    Adv Nurse Pract; 2006 Mar; 14(3):39-40, 42-3, 78. PubMed ID: 16548127
    [No Abstract]   [Full Text] [Related]  

  • 10. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D; Plosker GL
    CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.
    Dell'Agnello G; Zuddas A; Masi G; Curatolo P; Besana D; Rossi A
    CNS Drugs; 2009 Sep; 23(9):739-53. PubMed ID: 19689165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
    Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
    J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
    Eiland LS; Guest AL
    Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.
    Upadhyaya HP; Desaiah D; Schuh KJ; Bymaster FP; Kallman MJ; Clarke DO; Durell TM; Trzepacz PT; Calligaro DO; Nisenbaum ES; Emmerson PJ; Schuh LM; Bickel WK; Allen AJ
    Psychopharmacology (Berl); 2013 Mar; 226(2):189-200. PubMed ID: 23397050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-stimulant medications in the treatment of ADHD.
    Banaschewski T; Roessner V; Dittmann RW; Santosh PJ; Rothenberger A
    Eur Child Adolesc Psychiatry; 2004; 13 Suppl 1():I102-16. PubMed ID: 15322961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of atomoxetine.
    Sauer JM; Ring BJ; Witcher JW
    Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Harrington MJ; Burke WJ
    Expert Opin Pharmacother; 2003 Jul; 4(7):1165-74. PubMed ID: 12831341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S; Steer C
    Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine in the treatment of attention deficit hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Daughton JM; Mayfield-Jorgensen ML; Burke WJ
    Expert Rev Neurother; 2004 Jul; 4(4):601-11. PubMed ID: 15853579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
    Christman AK; Fermo JD; Markowitz JS
    Pharmacotherapy; 2004 Aug; 24(8):1020-36. PubMed ID: 15338851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.